This synergy between AI and drug development for aging is a promising avenue that will lead to significant solutions for aging and organ recovery challenges.

AI is used to improve organ recovery processes and extend the lifespan of artificial organs through real-time monitoring and adaptive responses. In the context of aging biology, we aim to improve patient outcomes in training for organ failure.

AI models analyze multi-omics datasets and combine information from the scientific literature to forecast potential therapeutic targets for aging.